Lead Discovery
Once a target protein implicated in a disease has been identified and validated, compound screening is performed to determine how small molecules interact with that specific target protein, by either activating or inhibiting it, for lead identification in drug discovery.
Featured Categories
We’re proud to offer a comprehensive portfolio of heterocyclic building blocks, one of the largest and most diverse families of molecular fragments used in organic synthesis.
Find the basic components needed to drive your research forward in our portfolio of organic building blocks. Alkenesm alkanes, alkynes, arenes, allenes & more!
Shop our diverse portfolio of halogenated heterocycles for use in a vast array of synthetic protocols, including lithiation and palladium-catalyzed cross-coupling methodologies.
With a vast offering of fluorinated building blocks, such as trifluoromethyl, difluoromethyl, triflate, and pentafluorosulfanyl substituents for your toolkit, we make it even easier to discover your target compounds.
To accelerate lead discovery, and thereby the rate of drug discovery, rapid and efficient screening technologies are essential. High-throughput screening (HTS) leverages automation and robotics for the quick analysis of large chemical compound libraries to ultimately detect compounds most suitable to pursue as drug candidates. DNA-encoded library (DEL) screening allows for mass conjugation of small molecule chemical compounds to short DNA fragments, so that a greater number of molecules can be examined for the desired activity and function simultaneously. In structure-based drug design screening, 3D structures of compounds are predicted using in silico techniques where entire libraries are docked into binding sites and the steric and electrostatic affinity between the compounds and target protein are evaluated. The highest-ranked compounds then progress to biological testing.
Hit-to-lead (H2L) research evaluates the pharmacodynamic, physiochemical, and pharmacokinetic properties of hits to identify lead compounds for lead optimization and further analysis as potential candidates for drug development.
Visit our document search for data sheets, certificates and technical documentation.
Related Articles
- Unprecedented access to large library drug discovery, Dynamic Library technology offers more reliable results than classical DEL approaches, library members selected for MedChem relevance, high chemical diversity, suitable for a number of targets
- We offer a wide variety of labeled bioactive compounds including steroids, vitamins, and their metabolites.
- MyriaScreen Diversity Collection of drug-like screening compounds
- DNA encoded libraries (DELs) offer a paradigm shift in drug discovery by leveraging molecular biology and high-throughput screening. DELs offer a full high-throughput screening library in one vial. Along with our DEL data package, machine learning and AI can be utilized to determine even more information on targets.
- See All (4)
Find More Articles and Protocols
How Can We Help
In case of any questions, please submit a customer support request
or talk to our customer service team:
Email custserv@sial.com
or call +1 (800) 244-1173
Additional Support
- Chromatogram Search
Use the Chromatogram Search to identify unknown compounds in your sample.
- Calculators & Apps
Web Toolbox - science research tools and resources for analytical chemistry, life science, chemical synthesis and materials science.
- Customer Support Request
Customer support including help with orders, products, accounts, and website technical issues.
- FAQ
Explore our Frequently Asked Questions for answers to commonly asked questions about our products and services.
To continue reading please sign in or create an account.
Don't Have An Account?